These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27120993)

  • 21. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY; Chong WS; Tey HL
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
    García-Doval I; Hernández MV; Vanaclocha F; Sellas A; de la Cueva P; Montero D;
    Br J Dermatol; 2017 Mar; 176(3):643-649. PubMed ID: 27258623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
    De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
    Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo onset of arthritis in patients previously treated with efalizumab: an observational case series.
    Colina M; Cianco G; Khodeir M; Sferra S; Scanavacca P; Corazza M; Virgili A; Trotta F
    Clin Exp Rheumatol; 2011; 29(1):141. PubMed ID: 21345301
    [No Abstract]   [Full Text] [Related]  

  • 27. New drugs and treatment targets in psoriasis.
    Kofoed K; Skov L; Zachariae C
    Acta Derm Venereol; 2015 Feb; 95(2):133-9. PubMed ID: 25111317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current therapeutic approaches of psoriasis are affected by age at disease onset.
    Di Lernia V; Ficarelli E
    J Dermatolog Treat; 2014 Feb; 25(1):15-7. PubMed ID: 23210896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasis Trends and Practice Gaps.
    Gottlieb AB; Greb JE; Goldminz AM
    Dermatol Clin; 2016 Jul; 34(3):235-42. PubMed ID: 27363878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.
    García García MJ; Rivero Tirado M; Callizo MEP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e89. PubMed ID: 30776300
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
    Burden AD; Warren RB; Kleyn CE; McElhone K; Smith CH; Reynolds NJ; Ormerod AD; Griffiths CE;
    Br J Dermatol; 2012 Mar; 166(3):545-54. PubMed ID: 22356636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies.
    Naldi L
    Clin Dermatol; 2010; 28(1):88-92. PubMed ID: 20082957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Puig L
    G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
    Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
    Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.